SAN FRANCISCO, CA — June 18, 2002 —
Treatment of obese patients with type 2 diabetes with a combination of insulin glargine (Lantus) and metformin improves glycemic control without causing hypoglycemia, a German group reported here Monday.
Speaking at the 62nd Scientific Sessions of the American Diabetes Association (ADA), the researchers said that this combination also has beneficial effects on lipid profiles, which has positive implications when considering the long-term health of these patients.
The combination also had a minimal effect on body weight. “The introduction of insulin analogs is a major clinical breakthrough in the management of diabetes,” said Dr. Danuta Stryjek-Kaminska, with the German Diagnostic Clinic in Wiesbaden.
Insulin glargine, a long-acting, once-daily human insulin analog, has been shown to have a unique, smooth action profile with no pronounced peaks. Improved metabolic control without weight gain poses a major challenge in the management of patients with type 2 diabetes.
Prior studies have shown that insulin glargine improves metabolic control, has a favorable weight profile, and reduces the risk of nocturnal hypoglycemia in patients with type 2 diabetes.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!